Agaoglu Sanli Bahar, Gulmez Barıs, Yazgan Serkan, Ucvet Ahmet
Dr Suat Seren Chest Diseases and Chest Surgery Training and Research Hospital, University of Health Sciences Turkey, Izmir, Turkey.
Van Training and Research Hospital, Thoracic Surgery Clinic, University of Health Sciences Turkey, Van, Turkey.
Updates Surg. 2024 Apr;76(2):631-639. doi: 10.1007/s13304-023-01669-3. Epub 2023 Oct 18.
Tumor markers are indicators that can be used not only for cancer diagnosis but also for determining prognosis. Unfortunately, there is currently no tumor marker that reliably predicts the prognosis of lung cancer. In this study, we investigated the prognostic impact of the platelet-to-lymphocyte ratio (PLR) and Glasgow Prognostic Score (GPS), known as inflammation markers in peripheral blood, in patients who underwent resection for early-stage non-small cell lung cancer (NSCLC). We retrospectively analyzed the medical records of a total of 3300 patients who underwent surgery for NSCLC between 2010 and 2020. Among these patients, 250 met the inclusion criteria of lobectomy, pT1-T2N0 stage, and histology of adenocarcinoma or squamous cell carcinoma. Preoperative albumin, C-reactive protein (CRP), preoperative PLR, and postoperative 5th-day PLR values were determined from patient's peripheral blood data. The impact of these values on postoperative recurrence and survival was investigated. GPS was calculated based on preoperative CRP and albumin values, and patients were divided into 3 groups: 0 (mild), 1 (moderate), and 2 (severe). The relationship between preoperative GPS and survival was analysed. Among the included patients, 155 (62%) had adenocarcinoma and 95 (38%) had squamous cell carcinoma. A total of 185 (74%) patients had pT1 tumors, while 65 (26%) had pT2 tumors. During the postoperative follow-up period, local recurrence was observed in 28 (11.2%) patients and distant metastasis in 51 (20.4%) patients. The overall mortality rate was 19.6%. The 5-year survival rates for pT1 and pT2 tumors were 80.4% and 72.5%, respectively. Significant associations were found between preoperative PLR, postoperative PLR, and recurrence (p = 0.005 and p = 0.011). The expected overall survival (OS) was 103.4 months in the mild GPS group, 91.8 months in the moderate GPS group, and 50 months in the severe GPS group. The relationship between GPS groups and OS was statistically significant (p = 0.005). Preoperative analysis of PLR and GPS may provide prognostic value in NSCLC patients who undergo surgical resection. Our study provides a rationale for further investigation of peripheral blood immune markers for prognostic purposes.
肿瘤标志物是不仅可用于癌症诊断,还可用于判断预后的指标。遗憾的是,目前尚无能够可靠预测肺癌预后的肿瘤标志物。在本研究中,我们调查了血小板与淋巴细胞比值(PLR)和格拉斯哥预后评分(GPS)(作为外周血中的炎症标志物)对接受早期非小细胞肺癌(NSCLC)切除术患者的预后影响。我们回顾性分析了2010年至2020年间共3300例接受NSCLC手术患者的病历。在这些患者中,250例符合肺叶切除术、pT1 - T2N0期以及腺癌或鳞状细胞癌组织学的纳入标准。从患者外周血数据中确定术前白蛋白、C反应蛋白(CRP)、术前PLR和术后第5天的PLR值。研究了这些值对术后复发和生存的影响。根据术前CRP和白蛋白值计算GPS,并将患者分为3组:0(轻度)、1(中度)和2(重度)。分析术前GPS与生存之间的关系。纳入的患者中,155例(62%)为腺癌,95例(38%)为鳞状细胞癌。共有185例(74%)患者为pT1肿瘤,65例(26%)为pT2肿瘤。在术后随访期间,28例(11.2%)患者出现局部复发,51例(20.4%)患者出现远处转移。总死亡率为19.6%。pT1和pT2肿瘤的5年生存率分别为80.4%和72.5%。术前PLR、术后PLR与复发之间存在显著关联(p = 0.005和p = 0.011)。轻度GPS组的预期总生存期(OS)为103.4个月,中度GPS组为91.8个月,重度GPS组为50个月。GPS组与OS之间的关系具有统计学意义(p = 0.005)。术前分析PLR和GPS可能为接受手术切除的NSCLC患者提供预后价值。我们的研究为进一步研究外周血免疫标志物的预后目的提供了理论依据。